HMPL-689
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 15/100
15
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma
Conditions
Lymphoma
Trial Timeline
Aug 26, 2019 → Jun 26, 2024
NCT ID
NCT03786926About HMPL-689
HMPL-689 is a phase 1 stage product being developed by HUTCHMED for Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03786926. Target conditions include Lymphoma.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04849351 | Phase 2 | Completed |
| NCT03786926 | Phase 1 | Terminated |
| NCT03128164 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoma